India's economic engine is revving up, but navigating the global headwinds requires sharp strategy. The rupee's recent volatility against the dollar underscores the complexities facing Indian businesses, impacting everything from import-export trade to domestic inflation. This week alone, we've seen significant shifts in the IT sector, with major players announcing restructuring and a renewed focus on AI-driven solutions. Meanwhile, the burgeoning startup ecosystem continues to attract substantial funding, despite a cautious global investor sentiment. The government's recent policy announcements on infrastructure development and digitalization are poised to further shape the business landscape, creating both opportunities and challenges for entrepreneurs and established corporations alike. Understanding these market dynamics is crucial for success in today's rapidly evolving Indian economy. Stay informed with Abtak.com for the latest insights and analysis on key sectors including finance, manufacturing, and technology – empowering your business decisions in a dynamic market. Explore the complete business news section now to stay ahead of the curve.
Granules India shares slipped sharply in trade, down nearly 10% after the company informed that US FDA has classified the inspection at Gagillapur facility in Hyderabad, Telangana as an 'Official Action Indicated' (OAI). The exchanges were informed about an inspection at the facility on September 7, which had resulted in a Form 483 issuance with six observations. Now, Granules India has said that it has responded to 'all the observations' issued by the USFDA. "The Company has responded to all the observations issued by the US FDA. Additionally, the Company has voluntarily undertaken a comprehensive evaluation of the facility for further enhancements that lead to improvement of the facility. This activity is undertaken in consultation with external subject matter experts," Granules India added. The pharma company said it intends to work with the US drug regulator and is confident of securing compliance for the facility soon. "The Company will work with the US FDA on this activity and is confident that it will result in the US FDA approving the Company's facility at Gagillapur in compliance with its expectations within a short time." A drug manufacturing facility that receives 'OAI'requires to re-establish its GMP and quality compliance with the US regulator. After the compliance norms are verified by the USFDA, the facility is inspected once again, before any further action from the drug authority. The latest development may imply the issues related to the Hyderabad facility may take longer to resolve. In a worst case scenario, the USFDA could escalate the matter with a warning letter, next, or worst, it may issue an import alert on the facility.
Granules Life Sciences (GLS) manufacturing facility in Shamirpet, near Hyderabad, has been classified as voluntary action indicated (VAI) by the U.S. Food and Drug Administration (U.S. FDA) consequent to an inspection in December 2025. The establishment inspection report (EIR) was issued following a current good manufacturing practice (cGMP) and pre-approval inspection (PAI) of the oral solid dosage manufacturing operations between December 15 and 19. The inspection is now closed and no regulato ...Read More >
Glenmark Pharmaceuticals disclosed receiving a warning letter from the U.S. FDA for its Indore facility following a February inspection. The company clarified that the letter won't impact existing supplies or revenues. It also emphasized its commitment to compliance and noted no data integrity issues were found. Glenmark Pharmaceuticals shares may be in focus on Monday, July 14, after the company disclosed that it has received a warning letter from the U.S. Food and Drug Administration (FDA) for ...Read More >
Dr Reddy's Laboratories has received a report from the US Food and Drug Administration. The report concerns its manufacturing facility in Srikakulam, Andhra Pradesh. The USFDA has classified the inspection outcome as Voluntary Action Indicated. This means the inspection is officially closed. The company received the Establishment Inspection Report on October 20, 2025. Drugmaker Dr Reddy's Laboratories Ltd on Tuesday said it has received establishment inspection report from the US health regulato ...Read More >
Hyderabad : Granules India Limited today announced that its wholly owned subsidiary, Granules Life Sciences Private Limited (GLS), has concluded a recent US FDA inspection of its manufacturing facility at Shamirpet, Telangana, with an inspection classification of Voluntary Action Indicated (VAI). The Establishment Inspection Report (EIR) was issued following a current Good Manufacturing Practice (cGMP) and pre approval inspection (PAI) of the oral solid dosage manufacturing operations conducted between December 15 and 19, 2025. The inspection is now closed, and no regulatory action has been ...Read More >